- Stem-cell muscle patches stabilized a failing heart, allowing a patient to survive until a transplant was available.
- The patches successfully integrated with the heart, forming blood vessels without causing irregular heartbeats or immune rejection.
- Researchers plan to expand trials, offering hope for heart failure patients awaiting transplants.
A pioneering clinical trial has demonstrated that muscle patches grown from stem cells can help stabilize failing hearts, marking a significant step forward in regenerative medicine. The procedure was tested on a 46-year-old woman who had suffered a heart attack in 2016 and later developed heart failure. During surgery, doctors implanted 10 patches containing 400 million cells onto the surface of her heart. The intervention kept her condition stable for three months, allowing her to receive a heart transplant.
Scientists later examined her removed heart and found that the implanted muscle patches had integrated well, remaining in place and forming blood vessels. The findings, published in Nature on January 29, suggest that stem-cell-derived muscle patches could serve as a temporary but effective treatment for patients awaiting heart transplants. The trial builds on earlier research conducted in rhesus macaques, where patches containing between 40 million and 200 million cells were tested.
With an estimated 60 million people worldwide living with heart failure, finding new treatment options is critical. Severe cases have a high mortality rate, and only a small percentage of patients receive life-saving heart transplants due to donor shortages. While artificial heart pumps exist, they are expensive and require invasive procedures. The new muscle patch therapy does not replace the need for transplants but offers a promising alternative for patients waiting for donor hearts.
The research team developed the patches using induced pluripotent stem cells (iPSCs), which are reprogrammed from adult cells to grow into different tissue types. By engineering these cells into heart muscle and connective tissue and embedding them in a collagen gel, they created a material that can be implanted with minimal invasion. Unlike previous approaches that injected stem cells directly into the heart—sometimes leading to complications such as irregular heartbeats or immune rejection—this method keeps the graft positioned outside the heart, reducing risks.
So far, the team has implanted similar muscle patches in 15 patients and plans to expand the trial. While further studies are needed to assess long-term effectiveness and safety, the results suggest that stem-cell-based muscle patches could play a vital role in bridging the gap between heart failure and transplantation. If successful, this approach could provide a much-needed option for patients currently left with few alternatives.
